The state of Iowa currently has 20 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Iowa City, Des Moines, Sioux City and Cedar Rapids.
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Type 1 Diabetes, Obesity, Overweight
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/21/2025
Locations: Iowa Diabetes Research, West Des Moines, Iowa
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Mercy Medical Center, West Des Moines, Iowa
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Iowa Preventive Intervention Clinic, Iowa City, Iowa
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Recruiting
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Iowa Diabetes & Endocrinology Research Center, West Des Moines, Iowa
Conditions: Overweight, Type 2 Diabetes, Obesity
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Recruiting
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Diabetes Mellitus, Type 1
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/12/2025
Locations: MercyOne Iowa Heart Center, West Des Moines, Iowa
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
Recruiting
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
05/07/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Gestational Diabetes
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
Recruiting
The purpose of this investigation is to examine the role of oxidative stress in aberrant microvascular function in otherwise healthy women with a history of GDM.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/07/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Gestational Diabetes, Vascular Endothelial Function
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
Recruiting
The purpose of this investigation is to examine NADPH oxidase as a source of reactive oxygen species contributing to aberrant microvascular function in otherwise healthy women with a history of GDM.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/07/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Recruiting
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: Integrated Clinical Trial Services, Inc., West Des Moines, Iowa
Conditions: Type 2 Diabetes, Obesity
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Recruiting
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/14/2025
Locations: McFarland Clinic, Ames, Iowa
Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)